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Mycobacterium tuberculosis, the causative agent of tubercu-
losis, parasitizes host macrophages. The resistance of the tuber-
cle bacilli to the macrophage hostile environment relates to
their ability to impair phagosomematuration and its fusionwith
the lysosome, thus preventing the formation of the phago-lyso-
some and eventually arresting the process of phagocytosis. The
M. tuberculosis zinc-dependentmetalloproteaseZmp1has been
proposed to play a key role in the process of phagosome matu-
ration inhibition and emerged as an important player in patho-
genesis. Here, we report the crystal structure of wild-type Zmp1
at 2.6 A˚ resolution in complex with the generic zincmetallopro-
tease inhibitor phosphoramidon, which we demonstrated to
inhibit the enzyme potently. Our data represent the first struc-
tural characterization of a bacterial member of the zinc-depen-
dent M13 endopeptidase family and revealed a significant
degree of conservation with eukaryotic enzymes. However,
structural comparison of the Zmp1-phosphoramidon complex
with homologous human proteins neprilysin and endothelin-
converting enzyme-1 revealed unique features of the Zmp1
active site to be exploited for the rational design of specific
inhibitors that may prove useful as a pharmacological tool for
better understanding Zmp1 biological function.
The intracellular pathogen Mycobacterium tuberculosis
is the main etiological agent of human tuberculosis (TB),2 one
of the world’s deadliest diseases. According to the World
Health Organization 2010 Fact Sheet, one third of the world
population is exposed toM. tuberculosis, and 9 million people
develop active TB, with 2 million deaths per year. The already
high TB global burden is further exacerbated by the high mor-
tality rate of TB-infected individuals suffering fromHIV/AIDS.
Moreover, the pharmacological treatment of TB is long and
expensive, and misuse of first-line and second-line drugs
against TB can favor the development ofmultidrug-resistant or
extensively drug resistantM. tuberculosis strains, rendering ex-
tremely difficult the eradication of the pathogen by the most
effective anti-TB drugs (2).
The host organism deals withM. tuberculosis infection by a
series of innate and adaptive immune responses (3). InhaledM.
tuberculosis bacteria are phagocytosed by resident macro-
phages in the lungs, i.e. the alveolar macrophages, but not effi-
ciently cleared (4). In immunocompetent individuals the initial
acute infection is controlled by the immune system, and living
bacteria are confined in a peculiar localized pulmonary struc-
ture called granuloma. There, the bacteria can endure indefi-
nitely in a latent, nonvirulent form, and are reactivated when-
ever an immunosuppressive condition occurs (5).
A key step for successful bacterial clearance by macrophages
is phagosomematuration process, which culminates in the for-
mation of the phago-lysosome (6). However, some pathogens,
among them M. tuberculosis, have evolved the ability to pre-
clude the macrophages killing by inhibiting the phagosome
maturation process (7, 8). This step is critical for the progres-
sion of the infection because it compromises bacterial clearance
(9) and antigen processing (10, 11). Master et al. (12) proposed
thatM. tuberculosis is able to suppress phagosome maturation
by inhibiting the inflammasome (13). The inflammasome is a
multiprotein complex composed by members of the cytosolic
sensor proteins family called nucleotide binding oligomeriza-
tion domain which, once activated upon recognition of patho-
gen-associated molecules in the extracellular or the intracellu-
lar compartment, drives the activation of pro-caspase-1 (14,
15). Activated caspase-1, in turn, proteolitically activates pro-
IL-1 into IL-1, which, once secreted, in an autocrine and
paracrine fashion triggers the phagosome fusion with intracel-
lular lysosomes and the early inflammatory response (16).
Master et al. found that zmp1 gene (Rv0198c) suppresses
inflammasome activation by inhibiting caspase-1 activation,
thus preventing processing of pro-IL-1 into IL-1 and the
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consequent phagosome maturation. Nonetheless, they fur-
nish evidence that suppression of the zmp1 gene reestab-
lished the activation of caspase-1, the production of IL-1,
and the full maturation of the phagosome into phago-lyso-
some, leading to the clearance of the pathogen. In addition,
the authors showed that exogenously added IL-1 was suffi-
cient to determine bacteria clearance by the phago-lyso-
some. The authors therefore proposed that the blocking of
the phagosomematuration process is due to the inhibition of
the inflammasome by the secreted M. tuberculosis protein
Zmp1 (Zn-dependent metalloprotease-1).
In contrast to what was proposed by Master et al., a recent
report by Muttucumaru et al. (17) claims that deletion of the
zmp1 gene causes bacterial hypervirulence in a mouse model.
This differs fromwhat was observed previously byMaster et al.,
where zmp1 deletion led to virulence attenuation. However,
these two reports suggest a key role of Zmp1 duringM. tuber-
culosis pathogenicity, although its mechanism of action still
remains under debate.
BLAST and Pfam sequence analysis indicated that Zmp1 is
anM13 endopeptidase, a protein family present in a wide range
of organisms including mammals and bacteria, with the excep-
tion of yeast (18). M13 endopeptidases regulate the biological
activity of many hormones and peptides and are involved in
many important processes such as blood pressure regulation
(neprilysin, or NEP) (19), cardiovascular development (endo-
thelin-converting enzyme-1, or ECE-1) (20), prevention of
hemolytic reaction (KELL) (21) and phosphate homeostasis
(PHEX) (22).M13 endopeptidases are type II, single-pass trans-
membrane zinc-metallopeptidases with a hydrophobic N-ter-
minal section of about 20 amino acids spanning the cytoplasmic
membrane, and a large ectodomain of about 700 residues.,
Sequence analysis indicate that Zmp1, unlike NEP and ECE-1
and other members of the M13 family, lacks the N-terminal
sequence required for extracellular export (although Zmp1 has
been found in cell supernatants) (12) and the hydrophobic seg-
ment providing cell membrane anchoring.
AllM13 endopeptidases are characterized by three signature
motifs involved in the binding of Zn2 (HEXXH and EXXXD)
and substrate/inhibitor (VNAXY). The glutamate residue of the
HEXXHsignature fingerprint is essential for catalysis because it
polarizes the water molecule that facilitates the nucleophilic
attack to the substrate peptide bond (23).
To shed light on the so far uncharacterized process of inflam-
masome inhibition by M. tuberculosis, we solved the crystal
structure of Zmp1 in complex with the inhibitor phosphorami-
don. Our structural data reveal a significant structural conser-
vation with human zinc-dependent metalloproteases NEP (24)
and ECE-1 (25), thus identifyingM. tuberculosisZmp1 as a new
member of M13 Zn-dependent metalloproteases. However,
subtle differences are present in the catalytic site of Zmp1 that
could be exploited for the design of specific inhibitors against
the mycobacterial enzyme.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification—Full-length zmp1 was
cloned in pET100/D-TOPO vector (providing an N-terminal
enterokinase-cleavable His tag) and expressed in Esche-
richia coli BL21(DE3) cells. Bacteria were precultured over-
night in 2 TY medium and then diluted in 1 liter of 2 TY
medium. The absorbance (A) was constantly monitored until it
reached 0.6. The temperature was then shifted to 20 °C, and
protein expressionwas induced overnight by the addition of 0.5
mM isopropyl 1-thio--D-galactopyranoside. The cells were
pelleted and resuspended in 30ml of 1 PBS, pH 7.4, and lysed
using a mechanical disruption system (Basic Z apparatus; Con-
stant System). Pellet and supernatantwere separated by centrif-
ugation, and the supernatant was applied to a preequilibrated
nickel-nitrilotriacetic acid column (Qiagen) and incubated for
1 h at 4 °C. Resin was washed thoroughly with 1 PBS, pH 7.4,
and protein was eluted with a step gradient of imidazole. Pro-
tein eluted in 100 and 200 mM imidazole fractions.
The eluted protein was then diluted in 10 mM Tris, pH 8,
buffer and loaded on a Mono Q 5/50 column (GE Healthcare)
and washed thoroughly. Protein elution was performed apply-
ing a linear gradient of NaCl. Fractions containing the purified
proteinwere concentrated and loaded on a Sephacryl 200 16/60
gel filtration column pre equilibrated with 10 mM Tris, pH 8.
Zmp1 eluted as a monomer with a symmetric peak. Fractions
containing Zmp1 were pooled and used immediately for crys-
tallization or flash frozen in liquid nitrogen and stored at
80 °C.
Protein Crystallization and Structure Solution—Purified
Zmp1 was concentrated to 26 mg/ml using Vivaspin concen-
trators (Sartorius AG) with a molecular mass cut-off of 50 kDa.
Phosphoramidon ((N-(-rhamnopyranosyl-oxyhydroxy-phos-
phinyl)-L-leucyl-L-tryptophan); catalog no. R9382, Sigma) was
then added to the concentrated protein to a final concentration
of 1 mM. Protein concentration of 13 mg/ml was obtained by
mixing the phosphoramidon-complexed Zmp1 with gel filtra-
tion buffer in a 1:1 ratio. Initial crystallization screens were
performedwith anOryx4 Protein Crystallization Robot (Doug-
las Instruments Ltd.). First Zmp1 crystals were obtained using
the Hampton Crystal Screen 2. Optimized diffraction quality
crystalswere obtained bymixing 0.3l of reservoir solution (0.2
M ammonium sulfate, 0.1 M sodium acetate trihydrate, pH 4.6,
30% w/v polyethylene glycol monomethyl ether 2000) with 0.3
l of phosphoramidon-complexed Zmp1 concentrated at 13
mg/ml and were grown for 2 months at 20 °C. Crystals were
fished, cryoprotected with 30% glycerol, and flash frozen in liq-
uid nitrogen. Best crystal diffracted to 2.60 Å at ID14-EH1
beamline (Electrosynchrotron Research Facility, Grenoble).
Data were processed using MOSFLM (26) and scaled using
SCALA (27). Molecular replacement was performed using
PHASER (28) included in the PHENIX package (29) and using
the structure of NEP as the searchmodel (ProteinData Bank ID
code 1DMT). Automatic model building was performed using
AUTOBUILD of the PHENIX suite, allowing the fitting of 90%
of residues. The remaining residues were added manually.
Structure and sequence alignments relative to Fig. 1 were
performed using 3DCoffee (30) and ClustalW (31), respec-
tively, and edited with ESPript (32).
Structure was refined using COOT (33) and REFMAC (34)
by applying TLS refinement to model data anisotropy. Zmp1
structure was analyzed and validated using MOLPROBITY
(35). All molecular graphics images were produced using
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PyMOL (36) with the exception of Fig. 2C, prepared using the
UCSF Chimera package (37).
PDB Deposition—The coordinates and the structure factors
were deposited in the Protein Data Bank under ID code 3ZUK.
Determination of Phosphoramidon Inhibition Constant—
Phosphoramidon inhibition constantKiwas determined by fol-
lowing the inhibition of Zmp1 catalytic activity toward the
generic fluorogenic substrate for matrix metalloproteinases
(MMPs) MMP2/MMP7. This substrate consists of the amino
acid sequence PLGL flanked by the fluorophore/quencher sys-
tem methoxycoumarin/dinitrophenyl-alanine-arginine (full
sequence: MCA-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2; MCA
stands for (7-methoxycoumarin-4-yl)-acetyl; Dpa stands for
N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl. MCA is the
fluorophore, Dpa the quencher (MMP2/MMP7 product num-
ber 03-32-5032, Calbiochem). Several phosphoramidon con-
centrations, ranging from15 to 250 nM,were incubatedwith 0.5
nM Zmp1 in 100 mM Tris-HCl, 0.1% borate, 150 mM NaCl, and
10 mM CaCl2, pH 8.0, buffer at 37 °C. The fluorescence was
detected in anEclypse fluorometer (Varian) (excitation 320 nm,
emission 395 nm).
The inhibition constant Ki was calculated upon determina-
tion of the various Km values from the substrate concentration
dependence at several inhibitor concentrations and then plot-
ting data ofKm as a function of inhibitor concentration, as from
the following equation.
Km 
0Km  1  IKI  (Eq. 1)
RESULTS
Zmp1 Overall Structure and Active Site—Zmp1 was recom-
binantly expressed in E. coli, purified to homogeneity and co-
crystallizedwith the inhibitor phosphoramidon, ametabolite of
Streptomyces tanashiensis and a known broad spectrum inhib-
itor of Zn-dependent metalloproteases (38, 39). This molecule
is able to inhibit in a competitive fashion (at least up to a con-
centration of 0.25 M) the enzymatic activity of Zmp1 toward
the synthetic substrate MMP2/MMP7 with a Ki of 35  5 nM
(see supplemental Fig. 1). Orthorhombic crystals diffracted to
2.60 Å and contained two Zmp1 molecules in the asymmetric
unit. The structure of Zmp1 was solved by molecular replace-
ment using NEP as the search model. Automatic and manual
model building led to a refined model with R and Rfree factors
converging to 17.51 and 24,96, respectively. Data collection and
refinement statistics are summarized in Table 1. Zmp1 shares
31% homology and 48% similarity with both human NEP and
ECE-1 (Fig. 1) onto which it can be superimposed with a root
mean square deviation of 1.87 Å and 1.73 Å for 593 and 594 C
pairs, respectively. Zmp1 has two cysteines (Cys285 andCys629),
whereas NEP has 12 and ECE-1 14. Cys428 of human ECE-1
(Cys412 in rat ECE-1) is involved in vivo in the formation of an
intermolecular disulfide bond responsible for ECE-1 dimeriza-
tion (40). Zmp1, likeNEP, ismonomeric in solution (Ref. 24 and
present work; data not shown), and its two cysteines are not
involved in a disulfide bridge.
The structure of Zmp1 presents an oval shape with dimen-
sions of about 78 Å for the major axis and 60 Å for the minor
one. Overall, the structure is composed by twomainly -helical
lobes interconnected by several loops distributed over the pro-
tein equatorial line (Fig. 2,A andB). The enzyme catalytic site is
located between the two lobes and is accessible via two oppo-
sitely positioned small openings on the protein surface (Fig.
2C). The catalytic zinc ion is coordinated in a tetrahedral geom-
etry by the conserved residues His493 (2.2 Å) andHis497 (2.0 Å),
belonging to the signature motifs 493HEXXH497, by Glu560 (2.0
Å), part of the 560EXXXD564 signature fingerprint, and by the
O1 oxygen of the N-phosphoryl moiety of the inhibitor (2.0 Å,
Fig. 3A). The conserved residue Glu494 (HE494XXH), unlike
Glu560, is not involved in metal coordination. Instead, its OE1
atom forms a specific interactionwith theO2 of the phosphora-
midon N-phosphoryl group. This oxygen atom occupies the
position of the water molecule responsible for the nucleophilic
attack to the peptide substrate, as observed for other M13 fam-
ily enzymes (23). Thus, the substitution of the catalytic water
molecule with the phosphoramidon n-phosphoryl O2 atom
allows inhibition of Zmp1 catalysis.
Zmp1 Interactions with the Inhibitor Phosphoramidon—In
the catalytic site, electron density compatible with the inhibitor
molecule phosphoramidon was observed. Phosphoramidon is
held in place by an intricate network of interactions with Zmp1
(Fig. 3). The indole moiety of phosphoramidon L-tryptophan
makes -stacking interaction with Phe48, whereas the indole
NH group forms a hydrogen bond with Val451 main chain car-
bonyl group andAsn452(ND2), both belonging to the conserved
triad 451VNA453 (Fig. 3B). OD1 and ND2 groups of Asn452 are
hydrogen-bonded with the inhibitor L-tryptophan and L-leucyl
NH groups. The latter is also involved in hydrogen bonding
with Ala453 main chain carbonyl group and Glu494 OE2. Addi-
tionally, the conservedArg628 forms hydrogen bondswithmain
chain L-aspartyl carbonyl group. The inhibitor rhamnose moi-
ety does not make contacts with the protein and is exposed to
the solvent.
Zmp1 Interactions with N,N,N-Triethanolamine (TEA)—
Further electron density has been detected in close proximity to
TABLE 1
Data collection and refinement statistics of Zmp1
Data collection statistics
Beamline ESRF ID14-EH1
Space group P21212
Unit cell dimensions (Å), (°) a	 128.3, b	 198.8, c	 63.3
	 	 	 90.00
Resolution (Å) 30-2.60 (2.74-2.60)
Completeness (%) 95.0 (75.6)
Multiplicity 3.6 (2.3)
Observations 175,191 (12,734)
Unique reflections 48,222 (5,510)
I/(I) 12.2 (2.6)
Rmerge 0.10 (0.37)
Molecules per asymmetric unit 2
Solvent content (%) 54.9
Wilson B factor (A2) 40.4
Refinement statistics
R/Rfree (%) 17.51/24.96
Root mean square deviation
Bonds (Å)/Angles (°) 0.015/1.52
Ramachandran plot
Residues in preferred regions (%)
(no. of residues)
95.8 (1,251)
Residues in allowed regions (%)
(no. of residues)
4.1 (53)
Residues in disallowed regions (%)
(no. of residues)
0.15 (2)
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the phosphoramidon molecule and has been interpreted as
TEA (Fig. 3,B andC). Because TEAwas not added to any buffer
used along the purification and crystallization procedures, we
speculate it could likely be a contaminant of the phosphorami-
don preparation. This molecule is observed only in one of the
twoZmp1 subunits of the asymmetric unit (chainA)whereas in
the other (chain B) is replaced by three watermolecules match-
ing the positions of the TEA hydroxyl groups of chain A.
The TEA binding pocket is located within the catalytic site
and the molecule forms stabilizing interactions both with the
protein and the inhibitor phosphoramidon. All three hydroxyl
groups of TEA make hydrogen bonds with both phosphorami-
don and Zmp1 side chains: O3 with the NH2 of the noncon-
served Arg615, O7 with NH and the carboxylic group of the
L-tryptophan, and O10 with O2 of the phosphoramidon rham-
nose moiety. Additionally, the central amine group of TEA
makes a hydrogen bond with the nonconserved Arg616 (NH1).
Zmp1 Recognition Subsites—The S1 recognition subsite of
Zmp1 accommodates the rhamnose moiety of the inhibitor
(Fig. 4, A and B). Residues Tyr454 and Met446 do not interact
FIGURE 1. Structure and sequence alignments of M. tuberculosis Zmp1 with human NEP and ECE-1. Spirals and arrows indicate helices and -strands,
respectively. Red boxes with white characters indicate residue identity; red characters indicate residue similarity; blue-framed characters indicate similarities
between groups of residues. Residues that bind Zn2 are shown in yellow and labeled with a triangle. Residues that interact with phosphoramidon are shown
in green and labeled with a black circle. Catalytic Glu494 is shown in cyan and labeled with awhite circle. The two Arg residues of Zmp1 that make contact with
TEA are colored blackon a yellowbackground and are labeledwith a star; the correspondingnonconservedNEP and ECE-1 residues are coloredwhiteon a black
background.
FIGURE 2. A, overall structure of Zmp1. Colors are coded according to secondary structure and lobe location. Blue and red, -helices, upper and lower lobe,
respectively; orange and yellow,-sheets, upper and lower lobe, respectively; dark gray, loops. Phosphoramidon and TEA are shown in sticks. Zn2 is shown as
a gray sphere. B, rotation of Zmp1 90 °C clockwise along the vertical axis. C, section of Zmp1 showing electrostatic surface potential. In blue, positive charges;
in red, negative charges. Arrows indicate surface holes and cavities for product/substrate access to the catalytic site.
FIGURE 3. Interactions of Zmp1 (chainA)with zinc (A) phosphoramidon (B), and TEA (C). Zmp1 residues are rendered in dark gray sticks. Phosphoramidon
and TEA and the corresponding electron densities are colored orange and yellow, respectively. Electron densities are contoured at 1.4 .
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with the phosphoramidon rhamnose group, leaving it mostly
exposed to the solvent. These residues are conserved in ECE-1
(Tyr568 and Met560), whereas in NEP they are replaced by
Phe544 and Ser536.
The S1 subsite of Zmp1 is constituted mainly by hydropho-
bic residues, as observed also in NEP and ECE-1 (Fig. 4, C and
D). In Zmp1, residue Alaz489 (Val603 in ECE-1) is replaced in
NEPby aMet579,making theZmp1S1 subsitemore hydropho-
bic compared with that of NEP. The indolemoiety of the inhib-
itor makes -stacking interaction with the conserved Phe48 of
Zmp1 (Phe106 and Phe149 in NEP and ECE-1, respectively). All
of the other residues of the S1 subsite (Val490, Ile468, Phe473,
Ile603, and Trp604) do not interact with the inhibitor and form a
mostly hydrophobic pocket that presumably accommodates a
substrate with a large, hydrophobic P1 side chain.
The large S2 subsite of Zmp1 is the least conserved among
that of NEP and ECE-1 (Fig. 4, E and F). Only two residues of
Zmp1 are conserved in NEP and ECE-1: Phe48 and Trp604
(Phe106/Phe149 andTrp693/Trp714 inNEP/ECE-1, respectively).
In Zmp1, the hydrophobic Phe52 residue is replaced in NEP by
the charged, flexible residue Arg110 and in ECE-1 by the bulky
residue Trp153. Zmp1 residues Arg45 and Asp49 are substituted
in NEP by Tyr103 and Asp107, respectively. The small, charged
Zmp1 residues Thr44 and Thr606 are replaced in NEP by Arg102
and Gly695. Finally, Ser608 is changed in Tyr697 in NEP and in
Arg718 in ECE-1. All of these mutations not only alter the local
charge and hydrophobicity, but also vary the accessible volume
of the subsite. The differences among Zmp1, NEP, and ECE-1
S2 subsites may be relevant for the specificity of their respec-
tive natural substrate(s).
DISCUSSION
We report here the crystal structure of Zmp1 fromM. tuber-
culosis, a potential pharmacological target against tuberculosis.
It is to our knowledge the first crystal structure of a prokaryotic
M13 protease. Zmp1 shows significant structural similarity
with the human homologous proteins NEP and ECE-1 regard-
ing the overall molecular architecture, the structural arrange-
FIGURE 4. Comparison of Zmp1 S1, S1, and S2 subsiteswith NEP and ECE-1. A, Zmp1 (gray) and NEP (pink) S1 subsite. B, Zmp1 (gray) and ECE-1 (violet) S1
subsite. C, Zmp1 (gray) and NEP (pink) S1 subsite. D, Zmp1 (gray) and ECE-1 (violet) S1 subsite. E, Zmp1 (gray) and NEP (pink) S2 subsite. F, Zmp1 (gray) and
ECE-1 (violet) S2 subsite. Phosphoramidon molecule is colored in orange.
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ment, and the mode of binding observed in complex with the
inhibitor phosphoramidon. Residues forming the S1 subsite of
Zmp1 are identical to those of ECE-1 but differ from those of
NEP (Tyr454 and Met446 of Zmp1 are replaced by Phe544 and
Ser536 in NEP). The local increased hydrophobicity of Zmp1
comparedwith theNEPS1 subsite could indicate a higher affin-
ity for inhibitors carrying hydrophobic groups at the P1 site, as
observed for ECE-1 (41, 42). However, the S1 site leaves the
rhamnose moiety of the inhibitor exposed to the solvent and
plays a minor role in substrate selectivity, as reported for NEP
and ECE-1 (43–46).
The S1 subsite is highly conserved among Zmp1, NEP, and
ECE-1. The residues present in this subsite are all hydrophobic
with the exception, in NEP, of Met579 (Ala489/Val603 in Zmp1/
ECE-1, respectively). The slight difference in volume and
hydrophobicity of the S1 site resulting from this single muta-
tion may explain the moderate preference, for ECE-1, of inhib-
itors carrying a bulky hydrophobic group at the P1 site (1, 47,
48). A similar behavior could be envisaged also for Zmp1, as its
S1 subsite is entirely hydrophobic.
Residues of the S2 subsite are less conserved compared with
those of the S1 and S1 subsites. Understanding themechanism
of S2 subsite specificitywould be useful for the individuation of
structural criteria that would serve as the rational basis for the
design of specific Zmp1 inhibitors.
The Zmp1 structure presented here bears in the catalytic
pocket a molecule that we identified as TEA. In the crystal
structure of NEP (24), a glycerol molecule occupies a position
equivalent to that observed for TEA in Zmp1 and, like TEA,
interacts both with NEP and phosphoramidon. Because TEA
and glycerol are two structurally different molecules that bind
to an equivalent pocket, we speculate that such a structural trait
might be of relevance in the family ofM13metalloproteases for
binding/recognition of nonsubstrate molecules possibly with
regulatory role. It should also be noticed that such a secondary
binding pocket shows peculiar features in different members of
the M13 family (Fig. 1). In particular, in Zmp1, TEA interacts
with two Arg residues (Arg615 and Arg616) that are structurally
nonconserved in humanNEP and ECE-1-homologous proteins
(Fig. 1). Therefore, the TEA binding pocket emerges as a prom-
ising docking site for the structure-based design of specific
Zmp1 inhibitors.
A matter of recent debate is the role played by Zmp1 in M.
tuberculosis pathogenesis. A recent paper (17) shows that
zmp1-deleted M. tuberculosis strains are hypervirulent, which
contrasts with the work of Master et al. (12), as they propose
that zmp1 deletion leads to virulence attenuation. Although the
issue awaits a definitive answer, the structure of Zmp1 reported
here will help the developing of specific inhibitors that may
prove useful both as a tool for further investigation of the bio-
logical functions of Zmp1 and as compounds of potential phar-
maceutical interest.
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